Jiangsu Kanion Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Jiangsu Kanion Pharmaceutical Co Ltd cash flow-to-debt ratio. Jiangsu Kanion Pharmaceutical Co Ltd (600557) has a Cash Flow-to-Debt Ratio of 0.11x as of September 2025, meaning its operating cash flow of CN¥201.83 Million could theoretically repay 0% of its total liabilities (CN¥1.83 Billion) in one year. Check Jiangsu Kanion Pharmaceutical Co Ltd (600557) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jiangsu Kanion Pharmaceutical Co Ltd (2001–2024)
Cash flow-to-debt ratio of Jiangsu Kanion Pharmaceutical Co Ltd from 2001 to 2024. Historical debt coverage capacity for Jiangsu Kanion Pharmaceutical Co Ltd across 24 annual periods. Check Jiangsu Kanion Pharmaceutical Co Ltd (600557) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Jiangsu Kanion Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2001–2024)
Jiangsu Kanion Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2001 to 2024. Year-by-year debt coverage analysis for Jiangsu Kanion Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of Jiangsu Kanion Pharmaceutical Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.32x | CN¥702.49 Million | CN¥2.20 Billion | ▼ -43.0% |
| 2023 | 0.56x | CN¥972.32 Million | CN¥1.74 Billion | ▲ +4.7% |
| 2022 | 0.53x | CN¥995.94 Million | CN¥1.86 Billion | ▼ -9.0% |
| 2021 | 0.59x | CN¥908.30 Million | CN¥1.55 Billion | ▲ +50.2% |
| 2020 | 0.39x | CN¥701.10 Million | CN¥1.79 Billion | ▼ -14.5% |
| 2019 | 0.46x | CN¥925.73 Million | CN¥2.02 Billion | ▲ +23.0% |
| 2018 | 0.37x | CN¥636.39 Million | CN¥1.71 Billion | ▲ +74.9% |
| 2017 | 0.21x | CN¥382.93 Million | CN¥1.80 Billion | ▲ +8.4% |
| 2016 | 0.20x | CN¥299.02 Million | CN¥1.52 Billion | ▼ -45.4% |
| 2015 | 0.36x | CN¥514.80 Million | CN¥1.43 Billion | ▲ +84.3% |
| 2014 | 0.19x | CN¥311.54 Million | CN¥1.60 Billion | ▼ -24.8% |
| 2013 | 0.26x | CN¥388.11 Million | CN¥1.50 Billion | ▲ +80.1% |
| 2012 | 0.14x | CN¥212.11 Million | CN¥1.47 Billion | ▲ +76.5% |
| 2011 | 0.08x | CN¥90.19 Million | CN¥1.11 Billion | ▼ -63.6% |
| 2010 | 0.22x | CN¥166.40 Million | CN¥743.19 Million | ▲ +476.0% |
| 2009 | -0.06x | CN¥-21.87 Million | CN¥367.23 Million | ▼ -136.3% |
| 2008 | 0.16x | CN¥58.39 Million | CN¥355.85 Million | ▼ -16.2% |
| 2007 | 0.20x | CN¥92.73 Million | CN¥473.81 Million | ▼ -20.4% |
| 2006 | 0.25x | CN¥108.98 Million | CN¥443.19 Million | ▲ +29.1% |
| 2005 | 0.19x | CN¥101.44 Million | CN¥532.62 Million | ▲ +225.8% |
| 2004 | 0.06x | CN¥21.68 Million | CN¥370.88 Million | ▲ +37.8% |
| 2003 | 0.04x | CN¥17.13 Million | CN¥403.56 Million | ▼ -64.7% |
| 2002 | 0.12x | CN¥11.15 Million | CN¥92.69 Million | ▼ -40.7% |
| 2001 | 0.20x | CN¥21.02 Million | CN¥103.61 Million | — |